User profiles for KOICHI MITSUYA
Koichi MitsuyaStaff, Neurosurgery, Shizuoka Cancer center Verified email at scchr.jp Cited by 2057 |
Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery
K Mitsuya, Y Nakasu, S Horiguchi, H Harada… - Journal of neuro …, 2010 - Springer
After stereotactic radiosurgery (SRS) for brain metastases, delayed radiation effects with
mass effect may occur from several months to years later, when tumors may also recur. …
mass effect may occur from several months to years later, when tumors may also recur. …
[HTML][HTML] Metastatic skull tumors: MRI features and a new conventional classification
K Mitsuya, Y Nakasu, S Horiguchi, H Harada… - Journal of neuro …, 2011 - Springer
Skull metastases are malignant bone tumors which are increasing in incidence. The
objectives of this study were to characterize the MR imaging features, locations, and extent of …
objectives of this study were to characterize the MR imaging features, locations, and extent of …
[HTML][HTML] α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial
…, T Ashizawa, M Yagoto, Y Abe, K Mitsuya… - BMC cancer, 2012 - Springer
Background High-grade gliomas including glioblastoma multiforme (GBM) are among the
most malignant and aggressive of tumors, and have a very poor prognosis despite a …
most malignant and aggressive of tumors, and have a very poor prognosis despite a …
[HTML][HTML] Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma
…, T Oishi, R Watanabe, K Mitsuya… - International …, 2013 - spandidos-publications.com
Signal transducer and activator of transcription (STAT) 3, a member of a family of DNA-binding
molecules, is a potential target in the treatment of cancer. The highly phosphorylated …
molecules, is a potential target in the treatment of cancer. The highly phosphorylated …
Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure
…, H Kenmotsu, H Murakami, H Harada, K Mitsuya… - Lung Cancer, 2011 - Elsevier
INTRODUCTION: Based on previous reports, patients who experience isolated central nervous
system (CNS) failure may not have systemic acquired resistance to EGFR-TKI therapy. …
system (CNS) failure may not have systemic acquired resistance to EGFR-TKI therapy. …
Antitumor effect of programmed death-1 (PD-1) blockade in humanized the NOG-MHC double knockout mouse
…, C Maeda, H Miyata, T Sugino, K Mitsuya… - Clinical Cancer …, 2017 - AACR
Purpose: Humanized mouse models using NOD/Shi-scid-IL2rγ null (NOG) and NOD/LtSz-scid
IL2rγ null (NSG) mouse are associated with several limitations, such as long incubation …
IL2rγ null (NSG) mouse are associated with several limitations, such as long incubation …
Diagnostic accuracy of cerebrospinal fluid liquid biopsy and MRI for leptomeningeal metastases in solid cancers: A systematic review and meta-analysis
…, M Yamazaki, A Notsu, K Mitsuya… - Neuro-oncology …, 2023 - academic.oup.com
Background Cerebrospinal fluid (CSF) cytology remains the gold standard approach for
diagnosing of leptomeningeal metastases (LM), but has clinical problems due to its low …
diagnosing of leptomeningeal metastases (LM), but has clinical problems due to its low …
Leptomeningeal metastasis in ER+ HER2-advanced breast cancer patients: a review of the cases in a single institute over a 15-year period
J Watanabe, K Mitsuya, S Nakamoto, H Harada… - Breast Cancer Research …, 2021 - Springer
Purpose While leptomeningeal metastasis (LM) from estrogen receptor-positive, HER2-negative
advanced breast cancer (ER + HER2-ABC) has a poor prognosis, the details of ER + …
advanced breast cancer (ER + HER2-ABC) has a poor prognosis, the details of ER + …
Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of worse survival after resection in patients with brain metastasis
K Mitsuya, Y Nakasu, T Kurakane, N Hayashi… - Journal of …, 2017 - thejns.org
OBJECTIVE The median postoperative survival duration of patients with brain metastases
who undergo tumor resection is 12 months. Most of these patients die of systemic metastases …
who undergo tumor resection is 12 months. Most of these patients die of systemic metastases …
[HTML][HTML] Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas
S Deguchi, T Oishi, K Mitsuya, Y Kakuda, M Endo… - Scientific reports, 2020 - nature.com
T2-FLAIR mismatch sign is known as a highly specific imaging marker of IDH-mutant
astrocytomas. This study was intended to clarify what the T2-FLAIR mismatch sign represents by …
astrocytomas. This study was intended to clarify what the T2-FLAIR mismatch sign represents by …